RNAZ (TransCode) Earnings per share growth this year
TransCode Therapeutics (RNAZ) is scaling its clinical trials to expand into the oncology market, leveraging a unique targeted delivery system for RNA drugs that will ensure significant pricing power. The company's operations rely on a strict biohazardous waste disposal protocol within its laboratories. The annual change in EPS confirms these fundamentals, with its latest value recorded as 0.00.
Financial and market metric breakdowns for transcodetherapeutics.com (RNAZ)
- stock value and consensus price forecast:
- business market valuation indicators:
- book capitalization information:
- debt burden and liquidity indicators:
Aggregate Debt to Capital TransCode Therapeutics|RNAZ - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital TransCode Therapeutics, Inc.|RNAZ - Company Aggregate Debts|Debts to Book Value TransCode Therapeutics|RNAZ - Company Long-Term Debt|Company Short-Term Loans and Borrowings TransCode Therapeutics|Quick Ratio transcodetherapeutics.com
- company profitability and valuation multiples indicators:
RNAZ - Company Net Income|Forward Earnings TransCode Therapeutics|RNAZ - P/E Multiple|Projected Price to Earnings Ratio TransCode Therapeutics, Inc.|RNAZ - Price/Earnings to Growth Multiple|EV/EBITDA Multiple TransCode Therapeutics|RNAZ - Operating profit before deduction of amortization|Earnings per share for the last four quarters TransCode Therapeutics|RNAZ - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months transcodetherapeutics.com|RNAZ - Earnings growth in current year|Expected earnings per share growth for next year TransCode Therapeutics
Fundamental valuation:RNAZ TransCode
The reliability of equity assets is assessed through capital efficiency dynamics and the business's ability to generate profit. This indicator captures the annual percentage change in earnings per share, filtering out market noise to identify the real profitability trend. The implementation of robotic DNA analysis systems at TransCode Therapeutics (RNAZ) optimizes costs, which is directly reflected in the measured growth of EPS YoY.
Main competitors
Earnings per share growth rate in current year Tempus Labs (TEM)|QGEN (Qiagen Group) - Earnings growth in current year|Earnings per share growth this year IONS (Isis Pharmaceuticals)|Earnings growth in current year RGEN|RNA - Earnings per share growth rate in current year|CRISPR Therapeutics - Net earnings per share growth this year|Earnings per share increase in current year WGS|RARE: Net earnings per share growth this year|Beam Tx - Net earnings per one share growth for the current year|SRPT: Earnings growth in current year|twistbioscience.com - Earnings per share increase in current year|TXG (10x Genomics) - Earnings growth in current year|Earnings per share growth rate in current year Intellia Therapeutics Inc NTLA|Earnings per share growth in current year Stoke (STOK)|BLFS (BioLife) - Earnings per share increase in current year|Earnings growth in current year WVE (Wave Life Sciences)|Earnings growth in current year mazetx.com MAZE|SION - Earnings per share growth in current year|Earnings per share trend in current year PRME|TSHA: Earnings growth in current year|Earnings per share growth rate in current year uniQure Pharma (QURE)|Net earnings per share growth this year MGTX|Earnings growth in current year regenxbio.com|Net earnings per share growth this year SLDB (Solid Biosciences)|Net earnings per one share growth for the current year OCGN|Earnings growth in current year PACB (Pacific Biosciences of California)|Expected net earnings per share growth this year Benitec Corp (BNTC)|Design Therapeutics - Earnings growth in current year|rocketpharma.com (RCKT) - Net earnings per share growth this year|4D Molecular Therapeutics, Inc. (FDMT) - Earnings per share growth in current year|LXEO - Expected net earnings per share growth this year|Earnings per share growth in current year Korro Bio Inc.|EDIT: Earnings per share increase in current year|Earnings per share growth in current year Silence Therapeutics (SLN)|proqr.com - Earnings per share growth this year|Earnings growth in current year CDXS (Codexis)|Earnings growth in current year Sangamo Therapeutics Inc. SGMO|NAUT: Net earnings per share growth this year|Earnings per share trend in current year MGX|DTIL: Earnings growth in current year|Earnings per share growth this year GBIO|Earnings per share growth in current year Boundless Bio|Earnings per share growth this year XCUR (Exicure Corp)|Earnings growth in current year IMNN|Earnings growth in current year phiopharma.com (PHIO)|Mustang Bio - Net earnings per share growth this year|Net earnings per one share growth for the current year BNGO (Bionano Genomics Inc.)|APDN - Earnings per share growth in current year|Earnings per share increase in current year BLUE (bluebird bio Inc.)|IPA: Earnings growth in current year|Omega Therapeutics Corp (OMGA) - Earnings growth in current year|Earnings per share growth in current year Singular Genomics Systems|Earnings per share growth this year RGLS (regulusrx.com)|Earnings per share growth in current year Syros Pharmaceuticals, Inc. (SYRS)|Expected net earnings per share growth this year Telesis Bio Inc.|Earnings growth in current year TCON (TRACON)|UBX - Net earnings per share growth this year
